We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+7.16%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$776M
AUM Growth
-$138M
(-15%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-22.7%
Top 10 Holdings %
Top 10 Hldgs %
36.6%
Holding
70
New
9
Increased
23
Reduced
28
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$19M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
+$18.6M |
| 3 |
Gilead Sciences
GILD
|
+$18M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$17.4M |
| 5 |
Molina Healthcare
MOH
|
+$14.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$25.7M |
| 2 |
DexCom
DXCM
|
+$24.4M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$20M |
| 4 |
Viatris
VTRS
|
+$19.2M |
| 5 |
NUVA
NuVasive, Inc.
NUVA
|
+$17.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
| $36.4M | 4.69% |
2,412,870
-1,071,120
| -31% | -$14.2M |
|
2
Pfizer
PFE
$143B
| $34.2M | 4.4% |
1,009,387
-472,505
| -32% | -$15.2M |
|
3
Novartis
NVS
$293B
| $32.9M | 4.24% |
428,316
-195,858
| -31% | -$14.8M |
|
4
Acadia Pharmaceuticals
ACAD
$4.38B
| $31M | 3.99% |
822,392
-276,417
| -25% | -$8.99M |
|
5
Johnson & Johnson
JNJ
$609B
| $30.6M | 3.94% |
235,349
-118,699
| -34% | -$15.7M |
|
|
PTLA
6
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $27.4M | 3.52% |
506,414
+84,271
| +20% | +$4.95M |
|
7
Teladoc Health
TDOC
$1.7B
| $24.3M | 3.13% |
733,379
+190,306
| +35% | +$6.24M |
|
|
LOXO
8
DELISTED
Loxo Oncology, Inc
LOXO
| $22.6M | 2.91% |
245,226
+23,431
| +11% | +$1.82M |
|
|
XLRN
9
DELISTED
Acceleron Pharma
XLRN
| $22.6M | 2.91% |
604,957
+458
| +0.1% | +$15.9K |
|
10
BioMarin Pharmaceuticals
BMRN
$11.5B
| $22.2M | 2.86% |
238,413
-74,969
| -24% | -$6.62M |
|
11
Medtronic
MDT
$106B
| $21.9M | 2.82% |
281,160
-117,200
| -29% | -$9.73M |
|
|
ABMD
12
DELISTED
Abiomed Inc
ABMD
| $21.7M | 2.79% |
128,671
-100,601
| -44% | -$15.2M |
|
|
LJPC
13
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $20.9M | 2.69% |
601,500
+11,541
| +2% | +$371K |
|
|
14
Merck
MRK
$315B
| $20.8M | 2.68% |
340,893
-423,605
| -55% | -$25.7M |
|
|
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
| $20.7M | 2.67% |
251,699
+219,799
| +689% | +$17.4M |
|
|
TSRO
16
DELISTED
TESARO, Inc.
TSRO
| $19.3M | 2.49% |
+149,799
| New | +$18.6M |
|
|
17
UnitedHealth
UNH
$387B
| $19.2M | 2.48% |
+98,205
| New | +$19M |
|
|
18
Gilead Sciences
GILD
$167B
| $19M | 2.45% |
+234,900
| New | +$18M |
|
|
KTWO
19
DELISTED
K2M Group Holdings, Inc
KTWO
| $19M | 2.45% |
896,714
-131,505
| -13% | -$3.05M |
|
|
CELG
20
DELISTED
Celgene Corp
CELG
| $18.8M | 2.42% |
128,932
-104,836
| -45% | -$14.3M |
|
21
Collegium Pharmaceutical
COLL
$1.17B
| $18.4M | 2.36% |
1,749,457
-59,293
| -3% | -$654K |
|
|
AERI
22
DELISTED
Aerie Pharmaceuticals
AERI
| $18.1M | 2.34% |
373,396
-29,278
| -7% | -$1.6M |
|
|
GBT
23
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $16.6M | 2.13% |
533,708
+80,927
| +18% | +$2.28M |
|
24
Acadia Healthcare
ACHC
$3.17B
| $15.7M | 2.03% |
329,510
-273,700
| -45% | -$13.3M |
|
|
25
Molina Healthcare
MOH
$11.7B
| $15.2M | 1.95% |
+220,359
| New | +$14.3M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q3 2017 Portfolio in Review
As of Q3 2017, Sectoral Asset Management held 70 positions worth $776M, down 15% from $914M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Sectoral Asset Management withdrew a net $176M in Q3 2017, closing 8 positions and reducing 28 holdings. Its most notable exit was DexCom, an estimated $24.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier.
Against the trend, Sectoral Asset Management opened a new position in UnitedHealth worth $19.2M.
- Sectoral Asset Management's largest Q3 2017 buy was UnitedHealth: 98,205 shares worth $19.2M.
- Sectoral Asset Management added most to Clovis Oncology, Inc. in Q3 2017, an estimated $17.4M increase.
- Sectoral Asset Management's biggest Q3 2017 reduction was Merck, cutting an estimated $25.7M.
- Sectoral Asset Management fully exited DexCom in Q3 2017, selling an estimated $24.4M.
- Sectoral Asset Management's ten largest holdings make up 37% of its $776M portfolio in Q3 2017.
- Sectoral Asset Management opened 9 new positions and closed 8 in Q3 2017.
- Sectoral Asset Management's portfolio value fell 15% quarter-over-quarter to $776M.
Based on Sectoral Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.